美国大型IRIS注册队列中新生血管性年龄相关性黄斑变性接受布罗鲁单抗治疗的一年结局
本研究基于美国IRIS注册数据库,回顾性分析2308只眼接受布罗鲁单抗治疗12个月的效果。结果显示多数治疗经治眼注药间隔延长,83.1%的眼在12个月时间隔达8周以上,同时视力保持稳定或改善。作者认为在权衡获益与风险后,换用布罗鲁单抗可能为高治疗负担患者提供延长间隔的优势。
要点
- 治疗初治眼83.7%(184/220)和治疗经治眼86.1%(1797/2088)在12个月时视力稳定或改善。
- 治疗经治眼中83.1%(1734/2015)在12个月时布罗鲁单抗注药间隔达8周以上,平均10.3±4.0周。
- 77.1%(1554/2015)的治疗经治眼注药间隔延长至少1周,其中55.4%(861/1554)延长至少4周。
核心结论
- 在基于社区的12个月研究中,布罗鲁单抗治疗使多数治疗经治眼的抗VEGF注药间隔延长,尤其是换药前间隔较短者,同时维持或改善视力。
- 作者认为,在仔细权衡获益与风险后,换用布罗鲁单抗可能为抗VEGF治疗负担高的患者提供延长治疗间隔的优势。
研究设计与样本
- 回顾性队列研究,基于美国IRIS注册数据库,纳入2079例患者共2308只眼,均为新生血管性年龄相关性黄斑变性且连续12个月仅接受布罗鲁单抗治疗。
- 纳入标准为首次注射布罗鲁单抗(索引)后12个月内接受2次及以上布罗鲁单抗注射且未换用其他抗VEGF药物。
主要发现
- 总体索引时视力为61.6±18.4个早期治疗糖尿病视网膜病变研究字母。
- 治疗初治眼83.7%(184/220)和治疗经治眼86.1%(1797/2088)在12个月时视力稳定(增减<10字母)或改善(增加≥10字母)。
- 在索引前365天内接受过抗VEGF注射的治疗经治眼中,29.5%(594/2015)换药前间隔为8周及以上(平均7.6±5.5周),而83.1%(1734/2015)在12个月时布罗鲁单抗注药间隔为8周及以上(平均10.3±4.0周)。
- 77.1%(1554/2015)的治疗经治眼注药间隔延长至少1周;其中55.4%(861/1554)延长至少4周。
临床怎么用
- 作者认为,在仔细权衡获益与风险后,换用布罗鲁单抗可能为抗VEGF治疗负担高的患者提供延长治疗间隔的优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate visual acuity (VA) and injection intervals in patients with neovascular age-related macular degeneration (nAMD) after 12 months of brolucizumab therapy in clinical practice. DESIGN: Retrospective cohort study. PARTICIPANTS: Adults in the United States-based IRIS® Registry (Intelligent Research in Sight) with nAMD who received brolucizumab exclusively for 12 months (2308 eyes of 2079 patients). METHODS: Observational study of eyes with a first injection of brolucizumab (index), followed by 2 or more brolucizumab injections over the following 12 months without switching to another anti-vascular endothelial growth factor (VEGF) agent. MAIN OUTCOME MEASURES: Primary outcomes were change in best recorded VA and, for eyes receiving prior anti-VEGF therapy (treatment-experienced eyes), the difference between the brolucizumab injection interval at 12 months and the anti-VEGF injection interval before switching. The interval before switching was defined as the time between the prior anti-VEGF and index brolucizumab injections; brolucizumab interval was the time between the closest injection to day 365 and the preceding injection. Secondary outcomes included incident adverse events. RESULTS: Overall VA at index was 61.6 ± 18.4 Early Treatment Diabetic Retinopathy Study letters; 83.7% of treatment-naive eyes (184/220) and 86.1% of treatment-experienced eyes (1797/2088) showed stable (< 10 letters gained or lost) or improved (≥ 10 letters gained) VA at 12 months. Among treatment-experienced eyes receiving a prior anti-VEGF injection within 365 days before index, 29.5% (594/2015) showed an interval before switching of 8 weeks or more (mean, 7.6 ± 5.5 weeks), whereas 83.1% (1734/2015) showed a brolucizumab injection interval at 12 months of 8 weeks or more (mean, 10.3 ± 4.0 weeks). In all, 77.1% of treatment-experienced eyes (1554/2015) showed an interval extension of 1 week or more; of these, 55.4% (861/1554) showed an extension of 4 weeks or more. CONCLUSIONS: In this community-based study, at 12 months, brolucizumab treatment prolonged the interval between anti-VEGF injections for most treatment-experienced eyes, particularly those with shorter intervals before switching, while maintaining or improving VA. With careful balancing of the benefits and risks, switching to brolucizumab treatment may offer the advantage of extending the treatment interval for patients with a high anti-VEGF therapy burden. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- MacCumber MW, Wykoff CC, Karcher H, et al. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry. Ophthalmology. 2023. PMID: 37086857. doi:10.1016/j.ophtha.2023.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。